Clinical usefulness of 18F-FDG PET/CT for the detection of distant metastases in patients with non-small cell lung cancer at initial staging: a meta-analysis
Authors Yu B, Zhu X, Liang Z, Sun Y, Zhao W, Chen K
Received 30 October 2017
Accepted for publication 9 April 2018
Published 4 July 2018 Volume 2018:10 Pages 1859—1864
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Kenan Onel
Binbin Yu,1,2 Xiaodong Zhu,1–3 Zhongguo Liang,1,2 Yongchu Sun,1,2 Wei Zhao,1,2 Kaihua Chen1,2
1Department of Radiation Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 2Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 3Department of Oncology, Affiliated Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
Background: We undertook a meta-analysis to evaluate the clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for the detection of distant metastases in patients with non-small cell lung cancer (NSCLC) at initial staging.
Materials and methods: All topic-related studies were comprehensively searched in the MEDLINE and Embase databases. We obtained the summary estimates and constructed the summary receiver operating characteristic curve for 18F-FDG PET/CT using the bivariate regression model.
Results: Across 10 studies (1333 patients), the sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio for 18F-FDG PET/CT were 0.81 (95% confidence interval [CI] = 0.63–0.92), 0.96 (95% CI = 0.94–0.98), 22.9 (95% CI = 13.3–39.5), and 0.20 (95% CI = 0.09–0.42), respectively. Overall weighted area under the curve was 0.97 (95% CI = 0.96–0.98).
Conclusion: 18F-FDG PET/CT has a good diagnostic performance for distant metastasis staging in patients with NSCLC at initial staging.
Keywords: 18F-FDG PET/CT, distant metastasis, lung cancer, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]